4F-MABP Stats & Data

4F‑MABP is a little‑studied fluorinated analogue of buphedrone first identified on the European NPS market in the mid‑2010s. Animal and seizure analyses on related cathinones indicate prevalent dopamine/norepinephrine transporter inhibition; potency and human pharmacodynamics for this exact compound remain uncertain—hence conservative dosing and slow titration are prudent. Synthetic cathinones frequently present with tachycardia, hypertension and peripheral vasoconstriction; people with cardiovascular disease, hypertension, or Raynaud‑like symptoms should avoid use. Hyperthermia can occur with stimulants in hot venues; balance fluids and electrolytes—avoid both dehydration and overhydration to reduce hyponatremia risk. Strong urges to redose and sleep loss can amplify anxiety or precipitate brief psychotic features; plan hard stops, secure sleep and recovery time, and avoid multiday runs. Intranasal use increases local harm (epistaxis, irritation) and infection risk; use sterile implements and saline care. Do not inject: cathinones are associated with acidic solutions, vasoconstriction and tissue injury, sharply increasing complication rates if injected. Avoid combinations that raise serotonin (e.g., MDMA) or lower seizure threshold (e.g., tramadol, bupropion). Always test material—multi‑reagent kits (e.g., Marquis, Froehde, Simon’s, Zimmermann, Morris) can help differentiate cathinone classes, but do not quantify potency.